Trifarotene Cream for Acne (START Trial)

"Two studies are presently being conducted with Trifarotene Cream in 34 cities across four nations. In 2021, 118 patients participated in the Phase 4 trial of this Galderma R&D-sponsored medication and since then seven other clinical trials have concluded."

"At this moment, there are 17 different clinical sites in the United States of America that are willing to enroll patients for this trial. These locations span from Las Vegas to Snellville and Darien; so you can easily find a centre closest to your residence if you decide to participate."

"Current information supplied by clinicaltrials.gov reveals that this study is not presently recruiting individuals. First listed on May 28th 2021, the trial was last edited October 14th 2022. However, 37 other trials are now enrolling patients for participation."

"In order to be considered for the trial, potential participants must fall between 17 and 35 years of age."

"At this moment, no further patients are being sought for the study. It was first made available to the public on May 28th 2021 and has been modified most recently on October 14 2022. For those in search of other trials related to acne, 35 studies remain active while two involve Trifarotene Cream directly."

"Currently, two trials exploring the use of Trifarotene Cream are in progress. Neither is at Phase 3 yet. Multiple medical centres located mostly around Arlington, Texas are testing this cream and altogether 43 sites across the US have already begun their research."

"This clinical trial aims to recruit 118 subjects, aged 17-35, who are suffering from acne. The following criteria must be met for inclusion: Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), no more than 2 nodules on the face (>1 cm in diameter), a minimum of 20 inflammatory lesions and 10 atrophic scars per half-face; females of childbearing potential must use approved contraceptives to treat acne vulgaris; other specified requirements may apply."

"Trifarotene Cream has been approved and thus, its safety rating is a 3 on our team's scale. This ranks it as one of the most secure treatments in this trial."